An interventional study of Non-invasive investigations and Invasive investigations in Multiple Sclerosis, Urinary Bladder, Neurogenic and Urodynamics, sponsored by Saint-Joseph University. Status unknown at 1 site in Lebanon. Per ClinicalTrials.gov, last updated 2018-09-06.
Sponsored by Saint-Joseph University · Not applicable, Interventional, and Diagnostic
Among 18 studies in Multiple Sclerosis with a site in Lebanon — none open to participants now, 1 under way, 1 of them phase 3. Multiple Sclerosis · Lebanon.
Among the 18 studies in Multiple Sclerosis with a site in Lebanon, this one is the 11th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2017, is one of 3 with no phase, and was the 13th registered.
3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.
Browse Multiple Sclerosis studies →None of the 18 studies in Multiple Sclerosis with a site in Lebanon is open now.
Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2017.
This study's planned enrollment of 60 is above the median of 50 across 2,201 interventional studies indexed under Multiple Sclerosis.
Median enrollment 329 across the 12 interventional studies, 836 across the 6 observational. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 10 most frequent:
Saint-Joseph University is the lead sponsor of 71 studies on the registry; 11 are open to participants now.
Saint-Joseph University has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Multiple Sclerosis with a site in Lebanon that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05134441Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
Among the 18 studies in Multiple Sclerosis with a site in Lebanon, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of the study is to describe the current status of MS patients with urinary disorders in Lebanon, and to demonstrate whether invasive investigations improve the management of these patients compared to an optimal non-invasive approach.
All patients will be evaluated by an urologist, then randomized into 2 groups, the first group will benefit from non-invasive investigations and will be treated accordingly, the second group will benefit from an urodynamic assessment and will also be treated accordingly.
An evaluation will be made one month, 3 months and 6 months after the first visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Non-invasive investigations include: ultrasound, blood exam, urine analysis and culture, uroflowmetry
Diagnostic Test: Non-invasive investigations
urodynamic study including: cystomanometry, pressure flow study, EMG
Diagnostic Test: Non-invasive investigations · Diagnostic Test: Invasive investigations
Ultrasound, blood tests, urine analysis and culture, uroflowmetry
Cystomanometry, pressure flow study, EMG
urinary symptoms
filling and voiding urinary symptoms (UBQMS: Urinary Bothersome Questionnaire in Multiple Sclerosis), Voising Score Ranges from 0 to 3 ( 3 being most severe bother), Filling score ranges from 0 to 3 ( 3 being most severe bother).
Time frame: 6 months
urinary quality of life
SF-QUALIVEEN: Short Form - health related quality of life questionnaire for urinary disorders in patients with neurological conditions. score ranges from 0 to 4 ( 4 being the worst quality of life).
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2017 (actual). Primary completion is estimated for Aug 2019, 22 months after the start.
Of 847 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's planned 22 months is close to that.
Counting every sponsor, half of 869 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saint-Joseph University